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Background: Although anti-tumor effect of monocyte-derived DC 
(M-DC) vaccine was studied in several tumor models with feasible 
responses, the major huddle is yield of therapeutic cells in culture. 
Hematopoietic stem cell-derived DC (S-DC) was introduced as alterna-
tives. In this study the in vivo anti-tumor effect of M-DC & S-DC was 
compared as well as the DC characters. 
Methods: Syngeneic Lewis lung carcinoma cells (LLC) were in-
oculated intravenously into C57BL/6 mice to simulate the minimal 
residual disease (MRD). M-DCs were cultured from myeloid lineage 
cells negatively selected from bone marrow cells by antibody panning. 
Selected cells were cultured with GM-CSF and IL-4 for 6 days. Mouse 
bone marrow stem cells were isolated by MACS lineage cell depletion 
kit and cultured with GM-CSF, SCF and IL-4 for 13days. Tumor anti-
gen pulsing was performed with autologous tumor cell lysate. Antigen 
pulsed therapeutic-DCs were injected twice by one week interval into 
the peritoneum of mice that are inoculated with LLC one day before the 
DC injection. Cultured therapeutic-DCs were characterized by pheno-
type and cytokine production nature. Anti-tumor responses and the im-
mune modulation were observed 2 weeks after the ﬁnal DC injection. 
Pulmonary tumor burden as well as tumor antigen speciﬁc lymphocyte 
proliferation (CFSE assay) and IFN-r secreting CD8+ T cell proportion 
(ELISPOT) were detected from the splenocytes of mice in each group. 
Results: Both M-DC and S-DC vaccine treatment inhibit the tumor 
growth in the lung. Especially anti-tumor response of tumor lysate 
pulsed DCs (LDCs) were signiﬁcant compared to saline treated mice. 
Over 90% M-DC & S-DC were expressed MHC I/II molecules. 
Interestingly, less than 10 % of M-DCs express CD11c but about 45 
% of M-DCs express CD11b. S-DC expresses CD11c in about 80% 
of the cells especially CD11c+CD8a+ proportions were about 35% 
in S-DC but less than 2% in M-DC. IL-12 secretion was higher in 
S-DC (424.82+87.26 pg/106 cells) than in M-DC (73.51+6.15 pg/106 
cells), but the secretion of IL-10 was higher in M-DC (65.99+4.30 vs. 
180.70+18.99 pg/106 cells for S-DC vs. M-DC respectively). Induction 
of tumor antigen-speciﬁc lymphocyte proliferation was only observed 
in M-DC/LDC treated group (2.6% vs. 60.5% proliferating cells by 
media vs. tumor lysate stimulation in vitro). However the frequency of 
IFN-r secreting CD8+ T cells were in S-DC treated group was signiﬁ-
cantly higher than that in M-DC treated group (58.7+8.3 vs. 11.7+1.8 
spots for S-DC/LDC vs. M-DC/LDC treated group, respectively). 
Conclusion: Although the characters of M-DC and S-DC were differ-
ent, anti-tumor effect of DC vaccines was similar in LLC MRD model. 
Tumor antigen speciﬁc lymphocyte proliferation was signiﬁcant in 
M-DC treated group, however as a effector cells the frequency of IFN-r 
secreting CD8+ T cells were higher in S-DC treated group than in 
M-DC group. Conclusively, data suggested that S-DC might be better 
module as anti-tumor vaccine than M-DC in both yield and function.
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Background: Cadi-05 has been undergoing evaluation in management 
of cancers. This double arm, controlled phase II study was undertaken 
to evaluate safety & efﬁcacy of Cadi-05 when used along with chemo-
therapy (Cisplatin plus Etoposide) for advanced stage Non Small Cell 
Lung Cancer (NSCLC).
Methods: Between January 2005 to June 2005 53 patients were ran-
domized to one of the treatment groups. Patient in Group A received 
Cisplatin and Etoposide (CE) along with intradermal administration 
of Cadi-05 (Mycobacterium W-0.5 x 109 cells/ml) 0.1 ml fortnightly 
for a period of 6 months & patients in Group B received Cisplatin 
and Etoposide. All the patients were required to complete 6 cycles of 
chemotherapy. 
Results: Of the 53 patients who were enrolled, 48 patients were 
eligible for ﬁnal analysis; 26 in group A & 22 in group B. Patients in 
Group A had a median survival of 11 months and patients in Arm B had 
a median survival of 7 months. One-year survival rates were 46.2% for 
Arm A and 36.4% for Arm B. Response rate was 38% in group A and 
27% in group B (see table 1). The most prevalent hematological toxici-
ties were neutropenia, leucopenia, and anemia, which were slightly less 
in the group A (13%, 5%, 4% resp) than in the group B (18%, 10%, 5% 
resp.). Common non hematological toxicities in both the group were 
asthenia, anorexia, vomiting and dyspnoea incidence of which were 
signiﬁcantly lesser in group A (21%, 13%, 8%, 7%) than in the group B 
(28%, 20%, 16%, 13% resp.) Patients in Group A tolerated the chemo-
therapy better, which resulted in higher compliance rate.
Conclusions: Higher compliance rate was observed in patients 
receiving Cadi-05. It improves response rate & median survival when 
administered as an adjuvant with chemotherapy containing Cisplatin 
plus Etoposide. 
TABLE 1: Response rate
 Responders Non Responders  
Group A 10 (38%) 16 (61.3%) 26
Group B 06 (27%) 16(72.4%) 22
Total 16 32 48
